

## Product datasheet for TR317855

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **DNAJC19 Human shRNA Plasmid Kit (Locus ID 131118)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** DNAJC19 Human shRNA Plasmid Kit (Locus ID 131118)

Locus ID: 131118

PAM18; TIM14; TIMM14 Synonyms:

Vector: pRS (TR20003) E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection: Format:

Retroviral plasmids

Components: DNAJC19 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

131118). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

NM 001190233, NM 145261, NM 201259, NM 201260, NM 201261, NR 033721, NR 033722, RefSeq:

NR 033723, NR 033724, NR 033725, NR 046073, NM 145261.1, NM 145261.2, NM 145261.3,

NM 001190233.1, BC073989, BC073989.1, BC009702, BM701756, BM702203, NM 145261.4

UniProt ID: Q96DA6

Summary: The protein encoded by this gene is thought to be part of a complex involved in the ATP-

> dependent transport of transit peptide-containing proteins from the inner cell membrane to the mitochondrial matrix. Defects in this gene are a cause of 3-methylglutaconic aciduria type 5 (MGA5), also known as dilated cardiomyopathy with ataxia (DCMA). Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on

chromosomes 1, 2, 6, 10, 14 and 19. [provided by RefSeg, Jan 2012]

These shRNA constructs were designed against multiple splice variants at this gene locus. To shRNA Design:

> be certain that your variant of interest is targeted, please contact <a href="techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).